Stay updated on KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.

Latest updates to the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page
- Check5 days agoChange DetectedA consolidated Locations section now lists North Carolina and South Carolina locations, replacing the prior North Carolina Locations and South Carolina Locations subsections. The footer now shows Revision: v3.3.3 and the HHS Vulnerability Disclosure link has been removed.SummaryDifference0.3%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedFooter revision from v3.3.1 to v3.3.2; no changes to study details or trial data.SummaryDifference0.1%

- Check34 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.1. No changes were made to the study details or user-facing content.SummaryDifference0.1%

- Check41 days agoChange DetectedThe government funding/operating status notice has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check55 days agoChange DetectedResults have been posted for the study, including primary and secondary outcomes (PFS, response rate, and overall survival) and related time frames. Updated study dates reflect the start date, primary completion date, and study completion date.SummaryDifference0.4%

- Check84 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference3%

Stay in the know with updates to KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KeyLargo: Pembrolizumab Combo in Gastric Cancer Clinical Trial page.